S222. CLINICAL UTILITY OF PHARMACOGENETIC TESTING IN SCHIZOPHRENIA TREATMENT

摘要

BackgroundAntipsychotics (APs), antidepressants (ADs) and mood stabilizers are essential components in treatment of most psychiatric disorders and in particular in schizophrenia. Unfortunately, among the various compounds which have been developed, lengthy trials are often required before the optimum medication treatment is found, i.e. with most significant symptom alleviation and minimal side effects. Thus, predictive factors would thus be extremely beneficial in clinical practice. The underlying reasons for this large inter-individualvariability in terms of treatment response are not fully understood. Important factors that influence drug dose, response and side effects include age, gender, patient compliance, constellation of symptoms, co-morbidity, and to a large extent genetic factors.